Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Kizzmekia Corbett and Barney Graham.
Kizzmekia Corbett
Connection Strength
4.529
Barney Graham
  1. SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Nature. 2020 10; 586(7830):567-571.
    View in: PubMed
    Score: 0.896
  2. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. N Engl J Med. 2020 10 15; 383(16):1544-1555.
    View in: PubMed
    Score: 0.895
  3. Prototype pathogen approach for pandemic preparedness: world on fire. J Clin Invest. 2020 07 01; 130(7):3348-3349.
    View in: PubMed
    Score: 0.890
  4. mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nat Immunol. 2021 10; 22(10):1306-1315.
    View in: PubMed
    Score: 0.241
  5. A high-throughput inhibition assay to study MERS-CoV antibody interactions using image cytometry. J Virol Methods. 2019 03; 265:77-83.
    View in: PubMed
    Score: 0.199
  6. Importance of Neutralizing Monoclonal Antibodies Targeting Multiple Antigenic Sites on the Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein To Avoid Neutralization Escape. J Virol. 2018 05 15; 92(10).
    View in: PubMed
    Score: 0.191
  7. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 09 17; 373(6561):1372-1377.
    View in: PubMed
    Score: 0.060
  8. Protective antibodies elicited by SARS-CoV-2 spike protein vaccination are boosted in the lung after challenge in nonhuman primates. Sci Transl Med. 2021 08 18; 13(607).
    View in: PubMed
    Score: 0.060
  9. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity. 2021 08 10; 54(8):1869-1882.e6.
    View in: PubMed
    Score: 0.060
  10. Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants. Science. 2021 Aug 13; 373(6556).
    View in: PubMed
    Score: 0.060
  11. SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques. Sci Immunol. 2021 06 15; 6(60).
    View in: PubMed
    Score: 0.059
  12. The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates. Sci Transl Med. 2021 05 12; 13(593).
    View in: PubMed
    Score: 0.059
  13. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine. N Engl J Med. 2021 04 15; 384(15):1468-1470.
    View in: PubMed
    Score: 0.058
  14. Serologic Cross-Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses. J Clin Immunol. 2021 07; 41(5):906-913.
    View in: PubMed
    Score: 0.058
  15. Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines (Basel). 2021 Jan 21; 9(2).
    View in: PubMed
    Score: 0.058
  16. A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Sci Rep. 2020 10 23; 10(1):18149.
    View in: PubMed
    Score: 0.057
  17. Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes. Cell Rep. 2020 10 27; 33(4):108322.
    View in: PubMed
    Score: 0.057
  18. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020 12 17; 383(25):2427-2438.
    View in: PubMed
    Score: 0.057
  19. An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. N Engl J Med. 2020 11 12; 383(20):1920-1931.
    View in: PubMed
    Score: 0.056
  20. Severe Acute Respiratory Syndrome Coronavirus 2 Prevalence, Seroprevalence, and Exposure among Evacuees from Wuhan, China, 2020. Emerg Infect Dis. 2020 Sep; 26(9):1998-2004.
    View in: PubMed
    Score: 0.056
  21. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020 06 11; 181(6):1436-1441.
    View in: PubMed
    Score: 0.055
  22. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. Cell. 2020 05 28; 181(5):1004-1015.e15.
    View in: PubMed
    Score: 0.055
  23. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020 03 13; 367(6483):1260-1263.
    View in: PubMed
    Score: 0.054
  24. Structural Definition of a Neutralization-Sensitive Epitope on the MERS-CoV S1-NTD. Cell Rep. 2019 09 24; 28(13):3395-3405.e6.
    View in: PubMed
    Score: 0.053
  25. Publisher Correction: Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018 Dec 10; 8(1):17823.
    View in: PubMed
    Score: 0.050
  26. Stabilized coronavirus spikes are resistant to conformational changes induced by receptor recognition or proteolysis. Sci Rep. 2018 10 24; 8(1):15701.
    View in: PubMed
    Score: 0.049
  27. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A. 2017 08 29; 114(35):E7348-E7357.
    View in: PubMed
    Score: 0.046
  28. Pre-fusion structure of a human coronavirus spike protein. Nature. 2016 Mar 03; 531(7592):118-21.
    View in: PubMed
    Score: 0.041
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.